Evidence map›Paper›PMID 40799550›Full record

ArticlebioRxiv : the preprint server for biology2025

Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for

Sanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins, Pamela J McShane, Tawanda Gumbo, Shashikant Srivastava

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Sanjay SinghDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0003-4601-5673
Avneesh ShrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Gunavanthi D BoorgulaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Mary C LongAdvanta Genetics, Tyler, Texas, USA; Section of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Brian RobbinsAdvanta Genetics, Tyler, Texas, USA; Section of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Pamela J McShaneAdvanta Genetics, Tyler, Texas, USA; Section of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
Tawanda GumboIMPI Biotechnology Company Incorporated, Tateguru, Zimbabwe.ORCID 0000-0001-7592-8012
Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.ORCID 0000-0002-8786-8851

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
Reinforcing old warriors to treat Mycobacterium kansasii in shorter durationR21AI148096 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2020 to 2021
$413k
NIAID NIH HHS R01 AI179827NIAID NIH HHS R21 AI148096
6 · The paper itself

Abstract

Background: IDSA guideline-based therapy achieves sputum culture conversion rates in 20-34% of patients with Methods: We performed minimum inhibitory concentrations (MICs) experiments followed by hollow fiber system model of MAB-LD (HFS-MAB) exposure-effect studies with sulbactam-durlobactam administered every 8h (q8h), q12h, and q24h, to identify target exposures. Next, the sulbactam-durlobactam target exposure plus ceftriaxone was administered in the HFS-MAB inoculated with three different MAB isolates, as was the sulbactam-durlobactam-ceftriaxone combination with epetraborole and omadacycline (SDCEO). Results: Ceftriaxone reduced sulbactam-durlobactam MICs by 8-tube dilutions. In the HFS-MAB, sulbactam-durlobactam microbial kill and antimicrobial resistance were linked to % time concentration persists above MIC (%T Conclusion: Sulbactam-durlobactam-ceftriaxone achieved the highest microbial kill encountered so far in the HFS-MAB. Sulbactam-durlobactam-ceftriaxone should be tested as the backbone for novel treatment shortening regimens.

Indexed as

combination regimens“double-double” β-lactam-β-lactamase inhibitorslung diseaseNontuberculous mycobacteriaprobability of target attainmenttarget redundancytherapy durationγ slopes

Identifiers

PMID40799550
PMCPMC12340849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.